D.E. Shaw & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

D.E. Shaw & Co’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$3.23M	–	4347
2023 Q4	$3.23M	Hold	10,000	–	–	﹤0.01%	2282
2023 Q3	$3.58M	Hold	10,000	–	–	﹤0.01%	2115
2023 Q2	$3.79M	Hold	10,000	–	–	﹤0.01%	2088
2023 Q1	$4.79M	Sell	10,000 -50,000	-83%	-$23.4M	0.01%	1964
2022 Q4	$25.2M	Sell	60,000 -39,000	-39%	-$15.7M	0.03%	775
2022 Q3	$41.3M	Buy	99,000 +7,700	+8%	+$3.84M	0.05%	473
2022 Q2	$45.2M	Buy	91,300 +48,400	+113%	+$25.2M	0.05%	445
2022 Q1	$24.2M	Buy	42,900 +11,200	+35%	+$6.75M	0.02%	902
2021 Q4	$24M	Buy	31,700 +21,700	+217%	+$16.2M	0.02%	960
2021 Q3	$7.46M	Buy	+10,000	New	+$7.49M	0.01%	1750
2019 Q2	–	Sell	-15,400	Closed	-$4.71M	–	3666
2019 Q1	$4.71M	Sell	15,400 -13,000	-46%	-$3.51M	0.01%	1581
2018 Q4	$6.59M	Buy	+28,400	New	+$7.62M	0.01%	1351

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co's BIO Position: Q1 2026 in Review

D.E. Shaw & Co increased its Bio-Rad Laboratories Class A (BIO) stake by 69% in Q1 2026, buying an estimated $955K and bringing the position to 8,145 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2825.

D.E. Shaw & Co first reported a position in BIO in Q2 2013 and has held it in 52 quarters since. The position peaked at $59.6M in Q3 2018. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

D.E. Shaw & Co held 8,145 shares of Bio-Rad Laboratories Class A worth $2.27M as of Q1 2026.
D.E. Shaw & Co bought 3,315 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $955K.
Bio-Rad Laboratories Class A made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2825 holding.
D.E. Shaw & Co first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 52 quarters since.
D.E. Shaw & Co's Bio-Rad Laboratories Class A position peaked at $59.6M in Q3 2018.
391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.